LungLifeAI Logo

Shareholder Information

Notice of Special Meeting

View Special Meeting Documentation

Other Exchanges and Trading Platforms

LungLife AI has not applied or agreed to have any of its securities admitted or traded on any other exchanges or trading platforms.

Shares in Issue

Number of AIM securities in issue: 25,485,982 shares are issued, called up and fully paid. The Company holds no shares in treasury. This figure should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

Significant Shareholdings

Significant shareholdersNo of Common Shares% of share capital
Simon Raab4,148,29316.3
Icahn School of Medicine at Mount Sinai2,469,8429.7
Octopus Investments Ltd1,968,7507.7
Unicorn Asset Management1,750,0006.9
Syno Ventures Master Fund LP1,673,6686.6
Frederick W Gluck1,530,5966.0
Stifel Nicolaus & Co1,424,7845.7
Investec Wealth & Management1,394,8395.5
Livzon Pharmaceutical Group Inc1,347,6535.3
Lombard Odier Asset Mgt1,268,3634.9
Accord Data Holdings954,0483.7
Killik Asset Mgt836,9643.3

Director Shareholdings

DirectorNo of Common Shares% of share capital
Roy Davis14,2040.06
Andy Boteler5,6810.02
Paul Pagano12,1230.05
David Anderson12,1230.05

Shares Not in Public Hands

Percentage of securities not in public hands: As of 29 February 2024 the percentage of common shares not in the public hands was 49.4%.

Restrictions in Transfer of AIM Securities

There are no restrictions on the transfer of the Company’s common shares.

UK City Code on Takeovers and Mergers

LungLife AI is not subject to the City Code because its registered office is outside the UK, the Channel Islands and the Isle of Man. As a result, certain of the protections that are afforded to shareholders under the City Code, for example in relation to a takeover of a company or certain stakebuilding activities by shareholders, do not apply to LungLife AI. Certain provisions have been inserted into LungLife AI’s Certificate of Incorporation that adopt similar procedures to the City Code in the event of any party (or parties acting in concert) obtaining 30 per cent or more of the voting rights attaching to the issued Ordinary Shares, but there is no assurance that the courts of Delaware will uphold or allow the enforcement of these provisions.

This page was last updated on: 29 February 2024

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.